AgingResearch.NewsJoin free

Phase 3Recruiting

A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of JADE101 Administered Subcutaneously in Participants With Immunoglobulin A Nephropathy (The EVERGREEN Study)

Sponsor
Jade Biosciences, Inc. (Industry)
Enrollment
480 planned
Conditions
IgA Nephropathy (IgAN)
Interventions
JADE101; Placebo
Ages
adults, older adults
Registry
NCT07902817, CTIS2026-527177-11-00

Full record on ClinicalTrials.gov

From the registry

This Phase 3 study will evaluate the safety and efficacy of JADE101 compared with placebo in adults with immunoglobulin A nephropathy (IgAN). The results will contribute to the overall clinical characterization of JADE101 in this patient population.

Primary outcomes

  • To evaluate the effect of JADE101 on Urine Protein Creatinine Ratio (UPCR) in participants with IgA nephropathy

History

  1. Study completion expected

  2. Primary completion expected

  3. Expected to start

  4. Now recruiting

    , from Not yet recruiting to Recruiting

  5. Last registry update

  6. Registered